Crescent Biopharma (CBIO) Other Non Operating Income (2013 - 2026)

Crescent Biopharma (CBIO) reported Other Non Operating Income of $1.4 million for Q1 2026, up 256.49% year-over-year from $405617.5 in Q1 2025, and up 13.15% quarter-over-quarter from $1.3 million in Q3 2025.

Crescent Biopharma (CBIO) Other Non Operating Income (2013 - 2026) Analysis & Trends

Crescent Biopharma (CBIO) has 8 years of Other Non Operating Income data on file, last reported at $1.4 million in Q1 2026.

  • Other Non Operating Income for Q1 2026 came in at $1.4 million, up 256.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 million (up 16.78% YoY), and the FY2017 annual result was $651212.0, up 528.3% from the prior year.
  • Other Non Operating Income climbed to $1.4 million in Q1 2026 per CBIO's latest filing, from $1.3 million in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $1.4 million in Q1 2026 and troughed at -$924000.0 in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Crescent Biopharma 486.92 Mn 297.76 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 1.45 Mn
Sep 30, 2025 1.28 Mn
Jun 30, 2025 -760,000.00
Mar 31, 2025 -924,000.00
Sep 30, 2018 944,409.00
Jun 30, 2018 870,139.00
Mar 31, 2018 363,704.00
Dec 31, 2017 278,004.00
Sep 30, 2017 231,634.00
Jun 30, 2017 102,079.00
Mar 31, 2017 39,495.00
Dec 31, 2016 29,673.00
Sep 30, 2016 32,063.00
Jun 30, 2016 21,813.00
Mar 31, 2016 20,097.00
Dec 31, 2015 5,823.00
Sep 30, 2015 3,302.00
Jun 30, 2015 2,638.00
Mar 31, 2015 3,564.00
Dec 31, 2014 4,378.00